GleamWall
中文EN

CSBR CHAMPIONS ONCOLOGY, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 771856 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.7%
TTM net income YoY-137.8%
TTM EPS YoY—
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—

Margins

Gross margin49.8%
Operating margin-1.7%
Net margin-1.8%
FCF margin-10.1%
EBITDA margin0.5%

Returns

ROE-29.8%
ROA-3.5%
ROIC (approx.)—
Asset turnover1.90x

Leverage & solvency

Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income5.04x
Accruals ratio14.0%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-07-312026Q4*2026-04-302026Q32026-01-312026Q22025-10-312026Q12025-07-312025Q4*2025-04-302025Q32025-01-312025Q22024-10-31
Income statement
Revenue$15.23M$13.84M$16.56M$15.04M$13.99M$12.36M$17.04M$13.49M
Cost of revenue$7.53M$6.81M$8.83M$7.26M$8.00M$7.27M$6.62M$7.43M
Gross profit$7.70M$7.03M$7.72M$7.77M$6.00M$5.08M$10.42M$6.06M
R&D expense$2.34M$2.12M$2.27M$2.62M$2.08M$1.96M$1.72M$1.69M
SG&A expense$2.67M$2.63M$2.98M$2.97M$2.57M$2.53M$2.40M$1.89M
Operating income-$409,000-$522,000-$276,000$185,000-$527,000-$2.01M$4.50M$732,000
Pretax income-$415,000-$495,000-$237,000$255,000-$452,000-$1.96M$4.52M$739,000
Income tax$11,000$172,000$42,000$18,000$14,000-$129,000$23,000$11,000
Net income-$426,000-$667,000-$279,000$268,000-$466,000-$1.83M$4.50M$728,000
EBITDA-$95,000-$222,000$65,000$542,000-$169,000-$1.61M$4.90M$1.13M
EPS (basic)-0.03—-0.020.02-0.03—0.330.05
EPS (diluted)——-0.020.02-0.03—0.310.05
Weighted avg. shares (diluted)——13.89M14.46M13.79M—14.36M14.02M
Balance sheet
Cash & equivalents$4.36M$4.87M$7.13M$8.52M$10.32M$9.79M$3.20M$2.75M
Receivables$13.60M$13.18M$12.07M$11.54M$9.47M$11.20M$15.78M$10.47M
Current assets$19.29M$19.22M$20.18M$21.33M$21.01M$22.36M$19.70M$14.08M
PP&E, net$3.79M$3.53M$3.71M$3.95M$4.23M$4.38M$5.04M$4.97M
Goodwill$335,000$335,000$335,000$335,000$335,000$335,000$335,000$335,000
Total assets$33.29M$26.99M$28.45M$30.16M$30.55M$32.34M$30.63M$25.24M
Current liabilities$18.73M$19.92M$20.68M$22.14M$22.70M$23.85M$19.87M$18.86M
Total liabilities$28.83M$22.92M$24.07M$25.93M$27.01M$28.57M$25.16M$24.56M
Shareholders' equity$3.89M$3.94M$4.28M$4.17M$3.51M$3.77M$5.47M$681,000
Shares outstanding13.92M13.89M13.89M13.89M13.79M13.78M13.71M13.70M
Cash flow statement
Operating cash flow-$492,000-$2.00M-$1.34M-$1.74M$600,000$6.87M$490,000-$283,000
Capital expenditure$55,000$239,000$37,000$242,000$46,000$253,000$42,000$94,000
Free cash flow-$547,000-$2.24M-$1.38M-$1.98M$554,000$6.62M$448,000-$377,000
Investing cash flow-$55,000-$238,000-$14,000-$242,000-$46,000-$253,000-$42,000-$94,000
Financing cash flow$33,000-$19,000-$36,000$168,000-$14,000-$32,000$0$239,000
Depreciation & amortization$314,000$300,000$341,000$357,000$358,000$400,000$398,000$399,000
Stock-based compensation$766,000$357,000$423,000$249,000$208,000$131,000$256,000$9,000
Share buybacks—————$0$0$0

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.